CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Hemobiotech Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Hemobiotech Inc
5001 Spring Valley Road
Suite 1040 - West
Phone: (972) 455-8950p:972 455-8950 Dallas, TX  75244  United States Ticker: HMBT HMBT

On 11/4/2013, the U.S. Securities and Exchange Commission revoked the registration of each class of registered securities of Hemobiotech Inc for failure to make required periodic filings with the Commission.
This company is no longer actively traded on any major stock exchange.

Business Summary
HemoBioTech, Inc. is a biopharmaceutical company engaged in the research and development of human blood substitute technology licensed from Texas Tech University Health Sciences Center (TTUHSC). The Company’s product, HemoTech, is an oxygen-carrying solution that performs like red blood cells. It addresses human blood substitute product in the United States and around the world. It also can address many of the medical, logistical and economical concerns associated with red blood cell transfusion. HemoTech is created by reacting bovine hemoglobin with three chemicals: o-adenosine 5'-triphosphate (o-ATP), o-adenosine and reduced glutathione (GSH). These chemicals permit chemical modification of the hemoglobin to create the observed beneficial activities of HemoTech and introduce changes to the hemoglobin that control oxygen affinity and other biological activities.
(Source: 10-K)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
12/31/200912/31/2009YesYes---

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chairman of the Board Robert A.Baron 72 10/26/2009 11/1/2004
Interim Chief Executive Officer, Independent Director Robert E.Dragoo 72 8/9/2010 1/28/2009
Vice Chairman of the Board GhassanNino 44 10/6/2003 10/6/2003
5 additional Officers and Directors records available in full report.

Business Names
Business Name
HEMOBIOTECH INC
Hemobiotech Inc.
Hemobiotech, Inc.
HMBT

General Information
Number of Employees: 1 (As of 5/20/2010)
Outstanding Shares: 23,693,434 (As of 5/26/2010)
Shareholders: 100
Stock Exchange: OTC
Federal Tax Id: 330995817
Fax Number: (302) 655-5049


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023